Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT01197469

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01197469
Other papers using this trial's data
  • Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial The Lancet. Respiratory medicine, 2014-04 DOI, PubMed 24717626

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01197469. Randomized; double masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2012-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?
Condition
Chronic Obstructive Pulmonary Disease
Intervention (Drug)
Tadalafil
Intervention (Drug)
Placebo
Lead sponsor
University of Dundee (class: other)
Collaborator
Chief Scientist Office of the Scottish Government (class: other government)
Collaborator
NHS Tayside (class: other government)
Collaborator
NHS Fife (class: other government)

Record details

Record id
cardio:ct-nct01197469
Content hash
31ec5930a01e6a0c8458641e7a24b650201845da59906892f7e254d54e93cab2